Landis John B. 4
4 · EyePoint Pharmaceuticals, Inc. · Filed Jun 23, 2021
Insider Transaction Report
Form 4
Landis John B.
Director
Transactions
- Award
Stock Option (Right to Buy)
2021-06-22+11,000→ 11,000 totalExercise: $13.13From: 2022-02-09Exp: 2031-02-09→ Common Stock (11,000 underlying) - Award
Restricted Stock Units
2021-06-22+2,500→ 2,500 totalExercise: $0.00From: 2022-02-09→ Common Stock (2,500 underlying)
Footnotes (1)
- [F1]Will fully vest on the one-year anniversary of the grant date.